CMS RBCS · Treatments · Injections and Infusions (nononcologic)

Injection - Hyaluronan or Derivative codes

16 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Treatment J7328 Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 15.55M services · est. ▼ 15.4% YoY · 12,061 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 7.58M observed fee-for-service services

See the national market for J7328 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7318 Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 7.68M services · est. ▲ 29.2% YoY · 41,331 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3.78M observed fee-for-service services

See the national market for J7318 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7320 Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 7.54M services · est. ▼ 12.0% YoY · 24,804 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3.63M observed fee-for-service services

See the national market for J7320 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7325 Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 6.30M services · est. ▼ 3.2% YoY · 42,478 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3.07M observed fee-for-service services

See the national market for J7325 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7329 Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2019 — first year this code appears in Part B claims

National scale 6.04M services · est. ▼ 15.6% YoY · 32,155 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 3.04M observed fee-for-service services

See the national market for J7329 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7322 Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 3.00M services · est. ▲ 49.5% YoY · 22,799 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.51M observed fee-for-service services

See the national market for J7322 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7332 Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 1.99M services · est. ▲ 51.2% YoY · 12,446 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 974,678 observed fee-for-service services

See the national market for J7332 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7331 Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 1.09M services · est. ▼ 27.4% YoY · 6,803 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 526,849 observed fee-for-service services

See the national market for J7331 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 521,173 services · est. ▲ 6.0% YoY · 49,918 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 257,446 observed fee-for-service services

See the national market for J7321 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7323 Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 496,596 services · est. ▼ 4.4% YoY · 64,527 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 245,705 observed fee-for-service services

See the national market for J7323 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7324 Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 373,728 services · est. ▼ 3.9% YoY · 44,796 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 187,669 observed fee-for-service services

See the national market for J7324 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3473 Injection, hyaluronidase, recombinant, 1 usp unit CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 261,043 services · est. ▲ 42.9% YoY · 237 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 130,200 observed fee-for-service services

See the national market for J3473 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7326 Hyaluronan or derivative, gel-one, for intra-articular injection, per dose CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 160,208 services · est. ▼ 2.3% YoY · 52,258 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 82,209 observed fee-for-service services

See the national market for J7326 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7327 Hyaluronan or derivative, monovisc, for intra-articular injection, per dose CMS descriptor · HCPCS
Medicare Part B claims

First observed 2015 — first year this code appears in Part B claims

National scale 153,256 services · est. ▲ 18.1% YoY · 48,043 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 76,345 observed fee-for-service services

See the national market for J7327 → ranked groups · states · 12-yr trend

HCPCS · Treatment J7333 Hyaluronan or derivative, visco-3, for intra-articular injection, per dose CMS descriptor · HCPCS
Medicare Part B claims

First observed 2020 — first year this code appears in Part B claims

National scale 3,731 services · est. ▼ 50.7% YoY · 644 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 2,059 observed fee-for-service services

See the national market for J7333 → ranked groups · states · 12-yr trend

HCPCS · Treatment J3470 Injection, hyaluronidase, up to 150 units CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 130 services · est. ▲ 2.0% YoY · 55 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 65 observed fee-for-service services

See the national market for J3470 → ranked groups · states · 12-yr trend